Medicare Enrolled
Dr. Sujal Shah, MD
Medical Oncology · Palm Springs, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Shah from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Shah? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Shah
Dr. Sujal Shah is a medical oncology in Palm Springs, FL, with 18 years in practice. Based on federal Medicare data, Dr. Shah performed 177,808 Medicare services across 4,952 unique beneficiaries.
Between the years covered by Open Payments, Dr. Shah received a total of $9,587 from 55 pharmaceutical and/or device companies across 541 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Shah is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 14% volume in FL$ $9,587 industry payments
Medicare Practice Summary
Medicare Utilization ↗177,808
Medicare services
Top 14% in FL for medical oncology
4,952
Unique beneficiaries
$20
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~9,878 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 39,400 | $43 | $157 |
| Iron infusion (Feraheme) | 37,740 | $0 | $3 |
| Nivolumab injection (Opdivo) | 35,640 | $24 | $88 |
| Denosumab injection (Prolia/Xgeva) | 10,440 | $18 | $64 |
| Anti-nausea injection (fosaprepitant) | 9,000 | $0 | $1 |
| Epoetin alfa injection (Procrit) for anemia | 7,400 | $6 | $25 |
| Injection, eflapegrastim-xnst, 0.1 mg | 4,752 | $25 | $105 |
| Paclitaxel chemotherapy injection | 4,504 | $0 | $0 |
| Injection, degarelix, 1 mg | 4,400 | $3 | $12 |
| Dexamethasone injection (steroid) | 3,150 | $0 | $0 |
| Immune globulin infusion (Gammagard) | 2,790 | $35 | $140 |
| Complete blood count (CBC) with differential | 2,354 | $8 | $23 |
| Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | 2,185 | $35 | $193 |
| Anti-nausea injection (ondansetron/Zofran) | 1,420 | $0 | $0 |
| Blood draw (venipuncture) | 1,300 | $8 | $11 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,280 | $1 | $3 |
| Office visit, established patient (20-29 min) | 1,209 | $70 | $285 |
| Administration of chemotherapy into vein, 1 hour or less | 856 | $106 | $428 |
| Office visit, established patient (30-39 min) | 839 | $102 | $400 |
| Injection, potassium chloride, per 2 meq | 700 | $0 | $0 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 694 | $24 | $94 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 591 | $3 | $12 |
| Injection of additional new drug or substance into vein | 488 | $13 | $50 |
| Drug injection, under skin or into muscle | 364 | $12 | $44 |
| Injection, carboplatin, 50 mg | 337 | $2 | $8 |
| Injection, fluorouracil, 500 mg | 331 | $2 | $6 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 326 | $133 | $601 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 262 | $52 | $211 |
| Infusion, normal saline solution , 1000 cc | 236 | $2 | $8 |
| Injection, diphenhydramine hcl, up to 50 mg | 231 | $1 | $3 |
| Injection, leucovorin calcium, per 50 mg | 230 | $3 | $13 |
| Administration of additional new drug or substance into vein, 1 hour or less | 214 | $53 | $208 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 181 | $28 | $104 |
| Injection, magnesium sulfate, per 500 mg | 178 | $1 | $2 |
| Infusion into a vein for hydration, 31-60 minutes | 165 | $26 | $107 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 163 | $59 | $238 |
| Infusion into a vein for hydration, each additional hour | 157 | $11 | $40 |
| Administration of chemotherapy into vein, each additional hour | 141 | $23 | $91 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 131 | $17 | $65 |
| Injection, zoledronic acid, 1 mg | 124 | $7 | $17 |
| Hospital follow-up visit, high complexity | 113 | $98 | $320 |
| New patient office visit (45-59 min) | 89 | $132 | $530 |
| Collection of blood sample from implanted device | 86 | $21 | $83 |
| Office visit, established patient (10-19 min) | 85 | $43 | $179 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 85 | $4 | $18 |
| Office visit, established patient, complex (40-54 min) | 77 | $145 | $568 |
| Irrigation of implanted venous access drug delivery device | 62 | $20 | $84 |
| New patient office visit, complex (60-74 min) | 60 | $172 | $701 |
| Initial hospital admission, high complexity | 53 | $145 | $621 |
| Initial hospital admission, moderate complexity | 41 | $106 | $426 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 34 | $139 | $521 |
| Telephone medical discussion with physician, 11-20 minutes | 33 | $70 | $283 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 27 | $16 | $63 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 25 | $1 | $5 |
| Drawing of blood for a medical problem | 18 | $80 | $319 |
| Telephone medical discussion with physician, 5-10 minutes | 17 | $46 | $175 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
23.8% high complexity
72.3% medium
3.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$9,587
Total received (2018-2024)
Avg $1,370/year across 7 years
Top 46% in FL for medical oncology
55
Companies
541
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,241 (96.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$345 (3.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$111
2023$963
2022$805
2021$316
2020$690
2019$3,987
2018$2,714
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$967
Medtronic, Inc.
$793
Janssen Biotech, Inc.
$618
AstraZeneca Pharmaceuticals LP
$575
Novartis Pharmaceuticals Corporation
$575
PFIZER INC.
$552
Lilly USA, LLC
$481
Genentech USA, Inc.
$472
Merck Sharp & Dohme Corporation
$442
Amgen Inc.
$436
Celgene Corporation
$337
Boehringer Ingelheim Pharmaceuticals, Inc.
$315
Incyte Corporation
$270
Seattle Genetics, Inc.
$217
GENZYME CORPORATION
$195
Astellas Pharma US Inc
$188
Takeda Pharmaceuticals U.S.A., Inc.
$165
Janssen Scientific Affairs, LLC
$113
Regeneron Healthcare Solutions, Inc.
$112
Bayer HealthCare Pharmaceuticals Inc.
$109
Alexion Pharmaceuticals, Inc.
$104
Merck Sharp & Dohme LLC
$102
Daiichi Sankyo Inc.
$99
SOBI, INC
$98
TerSera Therapeutics LLC
$96
Intuitive Surgical, Inc.
$89
Pharmacyclics LLC, An AbbVie Company
$83
Dova Pharmaceuticals
$76
Sobi, Inc
$75
Exelixis Inc.
$71
Ipsen Biopharmaceuticals, Inc
$69
Kyowa Kirin, Inc.
$62
Eisai Inc.
$61
Taiho Oncology, Inc.
$50
TOLMAR Pharmaceuticals, Inc.
$49
Janssen Pharmaceuticals, Inc
$44
EISAI INC.
$38
Puma Biotechnology, Inc.
$38
ABBVIE INC.
$32
TESARO, Inc.
$31
AMAG Pharmaceuticals, Inc.
$31
Verastem, Inc.
$25
Mylan Institutional Inc.
$23
Alnylam Pharmaceuticals Inc.
$23
JAZZ PHARMACEUTICALS INC.
$20
Array BioPharma Inc.
$18
MEDIVATION FIELD SOLUTIONS LLC
$18
Advanced Accelerator Applications
$18
Karyopharm Therapeutics Inc.
$17
Gilead Sciences, Inc.
$17
GlaxoSmithKline, LLC.
$17
EMD Serono, Inc.
$17
Pacira Pharmaceuticals Incorporated
$16
Rigel Pharmaceuticals, Inc.
$15
GE HealthCare
$13
Top 3 companies account for 24.8% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · Abraxane · Alecensa · Avastin · BAVENCIO · BOSULIF · Balversa · Bavencio · Braftovi · CABOMETYX · CALQUENCE · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DOPTELET · Da Vinci Surgical System · Doptelet · ELIGARD · ELIQUIS · ELITEK · EMPLICITI · ERBITUX · ERLEADA · Enhertu · Erleada · Exparel · FERAHEME · GAZYVA · GILOTRIF · GIVLAARI · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · INTELLIS ADAPTIVESTIM · Imbruvica · JADENU · JAKAFI · KANJINTI · KEYTRUDA · KISQALI · KYPHON Balloon Kyphoplasty · Kyprolis · LIBTAYO · LUMAKRAS · LUPRON DEPOT · LYNPARZA · Lenvima · Lonsurf · Lutathera · MEKINIST · MVASI · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · OPDIVO · OSTEOCOOL RF ABLATION SYSTEM · Ogivri · POTELIGEO · PROMACTA · RECOTHROM · Revlimid · SANCUSO · SARCLISA · SKYRIZI · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNCHROMEDII · Stivarga · TABRECTA · TAFINLAR · TAGRISSO · TASIGNA · TECENTRIQ · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · ULTOMIRIS · VENCLEXTA · VYXEOS · Venclexta · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · ZEJULA · ZOLADEX · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $5 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
28
Per 100K population
1.9
County median income
$81,115
Nearest hospital
HCA FLORIDA JFK HOSPITAL
3.2 mi
3.2 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Shah is a mixed practice specialist, with above-average Medicare volume (top 14% in FL), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Shah experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Shah performed 39,400 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Shah receive payments from pharmaceutical companies?
Yes. Dr. Shah received a total of $9,587 from 55 companies across 541 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Shah's costs compare to other medical oncologys in Palm Springs?
Dr. Shah's average Medicare payment per service is $20. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Shah) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Palm Springs
Browse medical oncologys in Palm Springs ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Medtronic, Inc. Payments to Doctors
See all physicians who received payments from Medtronic, Inc..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology